Patient-reported dyspnea in COPD reliability and association with stage of disease

Chest

Volumn 136, Issue 6, 2009, Pages 1473-1479

  Mahler, Donald A ^a   Ward, Joseph ^a   Waterman, Laurie A ^a   McCusker, Corliss ^b   ZuWallack, Richard ^b   Baird, John C ^a,c  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^c Psychological Applications   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT;

ADULT; AGED; ARTICLE; BREATHING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE SEVERITY; DYSPNEA; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; INSTRUMENT; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SELF REPORT;

EID: 73149097224     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-0934     Document Type: Article

References (36)

1. van den Bemt L, Schermer T, van Weel C. Rational monitoring of COPD: where do current clinical guidelines stand? Eur Respir J 2007; 29:1078-1081
2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532-555
3. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-946
4. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease: 2007 update. Can Respir J 2007; 14(suppl):5B-32B
5. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31:416-469
6. Mahler DA. Dyspnea: mechanisms, measurement, and management. In: Mahler DA, O'Donnell DE, eds. Measurement of dyspnea: clinical ratings. Boca Raton, FL: Taylor & Francis, 2005; 147-165
7. Bausewein C, Farquhar M, Booth S, et al. Measurement of breathlessness in advanced disease: a systematic review. Respir Med 2007; 101:399-410
8. Mahler DA, Waterman LA, Ward J, et al. Validity and responsiveness of the self-administered computerized versions of the Baseline and Transition Dyspnea Indexes. Chest 2007; 132:1283-1290
9. de Torres JP, Pinto-Plata V, Ingenito E, et al. Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. Chest 2002; 121: 1092-1098
10. Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:144-149
11. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655-2666
12. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177:75-81
13. Streiner DL, Norman GR. Health measurement scales. In: Anonymous reliability. Oxford, UK: Oxford University Press, 1995; 104-127
14. Bland M. An introduction to medical statistics. In: Anonymous clinical measurement. Oxford, UK: Oxford University Press, 1995; 265-269
15. Brooks SM. Task group on surveillance for respiratory hazards in the occupational setting. ATS News 1982; 8:12-16
16. Mahler DA, Ward J, Fierro-Carrion G, et al. Development of self-administered versions of the modified baseline and transition dyspnea indexes in COPD. J COPD 2004; 1:165-172
17. Eakin EG, Resnikoff PM, Prewitt LM, et al. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire; University of California, San Diego. Chest 1998; 113:619-624
18. Mahler DA, Ward J, Lentine TF, et al. Reliability of patient-reported dyspnea measures [abstract]. Am J Respir Crit Care Med 2008; 177:A522
19. Waterman LA, Ward J, McCusker C, et al. Reliability of patient-reported changes in dyspnea. [abstract]. Am J Respir Crit Care Med 2009; 179:A2912
20. Morris JF, Koski A, Johnson LC. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis 1971; 103: 57-67
21. Crapo RO, Morris AH, Clayton PD, et al. Lung volumes in healthy nonsmoking adults. Bull Eur Physiopathol Respir 1982; 18:419-425
22. Lang TA, Secic M. How to report statistics in medicine. In: Anonymous observing exposures and outcomes concurrently. Philadelphia, PA: American College of Physicians, 2006; 245-246
23. Fletcher CM, Elmes PC, Fairbairn AS, et al. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. BMJ 1959; 5147:257-266
24. Eakin EG, Sassi-Dambron DE, Ries AL, et al. Reliability and validity of dyspnea measures in patients with obstructive lung disease. Int J Behav Med 1995; 2:118-134
25. Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006; 27:822-832
26. Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med 1997; 127:1072-1079
27. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54:581-586
28. Mahler DA, Faryniarz K, Tomlinson D, et al. Impact of dyspnea and physiologic function on general health status in patients with chronic obstructive pulmonary disease. Chest 1992; 102:395-401
29. Wegner RE, Jorres RA, Kirsten DK, et al. Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. Eur Respir J 1994; 7:725-729
30. Di Marco F, Verga M, Reggente M, et al. Anxiety and depression in COPD patients: the roles of gender and disease severity. Respir Med 2006; 100:1767-1774
31. Cardoso F, Tufanin AT, Colucci M, et al. Replacement of the 6-min walk test with maximal oxygen consumption in the BODE Index applied to patients with COPD: an equivalency study. Chest 2007; 132:477-482
32. Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121:1434-1440
33. O'Donnell DE, Banzett RB, Carrieri-Kohlman V, et al. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc 2007; 4:145-168
34. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005-1012
35. Celli BR. Update on the management of COPD. Chest 2008; 133:1451-1462
36. Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:6-14